Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Formation of 13,14-dihydro-prostaglandin (PG) E1 during intravenous infusions of PGE1 in patients with peripheral arterial occlusive disease was investigated. Using both high performance liquid chromatography (h.p.l.c.) combined with radioimmunoassay and gas chromatography/triple stage quadrupole mass spectrometry (GC/MS/MS) basal levels of 13,14-dihydro-PGE1 were found to be close to or below the detection limits of the assay methods. Levels of the PGE1 metabolite increased significantly during the infusion periods and decreased after their end. Since 13,14-dihydro-PGE1, in contrast to its precursors 15-keto-PGE1 and 15-keto-13,14-dihydro-PGE1, is biologically active, its formation could contribute to the beneficial effects of PGE1 administered intravenously in patients with peripheral arterial occlusive disease.
Peskar
B A
BA
Department of Pharmacology and Toxicology, Ruhr University, Bochum, FRG.
Hesse
W H
WH
Rogatti
W
W
Diehm
C
C
Rudofsky
G
G
Schweer
H
H
Seyberth
H W
HW
D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000494:pharmacology*; D001157:Arterial Occlusive Diseases / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008297:Male; D011863:Radioimmunoassay
C069881:13,14-dihydroprostaglandin E1; D000527:Alprostadil